In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
2023 Annual Review of Antitrust Law Developments
CRA’s Yajing Jiang contributed to Chapter 1 “Restraints of Trade” of the 2023 Annual Review of Antitrust Law Developments recently published by the ABA...